ALT-803 is another variant of IL-15, among 21 patients with NSCLC, 29% achieved objective response and showed elevated levels of circulating NK and CD8+ T cells through subcutaneous co-administration of PD-1 inhibitor therapy [223]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.